Impel NeuroPharma Earnings Preview

Impel NeuroPharma (NASDAQ:IMPL) is set to give its latest quarterly earnings report on Friday, 2023-03-24. Here’s what investors…

Impel NeuroPharma (NASDAQ:IMPL) is set to give its latest quarterly earnings report on Friday, 2023-03-24. Here’s what investors need to know before the announcement.

Analysts estimate that Impel NeuroPharma will report an earnings per share (EPS) of $-1.11.

Impel NeuroPharma bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company missed EPS by $0.31, which was followed by a 9.52% drop in the share price the next day.

Here’s a look at Impel NeuroPharma’s past performance and the resulting price change:

Quarter Q3 2022 Q2 2022 Q1 2022 Q4 2021
EPS Estimate -1 -1.05 -1.05 -0.87
EPS Actual -1.31 -1.09 -1.17 -1.07
Price Change % -9.52% 1.15% 1.92% 2.79%

eps graph

Stock Performance

Shares of Impel NeuroPharma were trading at $1.1255 as of March 22. Over the last 52-week period, shares are down 86.03%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

To track all earnings releases for Impel NeuroPharma visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Lifeist Reports Highest Quarterly Gross Profit In History, Continues To Diversify Its Wellness Business

Lifeist Wellness Inc. reported on Monday its financial results for the three and 12 months ended Nov. 30, 2023. The Toronto-based company said it achieved the highest quarterly gross profit in the company's history in the fourth quarter totaling CA$2 million ($1.5 million), representing a gross margin of 42%, compared to CA$1.9 million, or 31% gross margin, in the corresponding quarter of 2022."Our performance in the fourth quarter of 2023 reflects our strategic focus on high-margin activities and operational efficiency, resulting in the highest quarterly gross profit in our company's history," Meni Morim, CEO of Lifeist, said. "Though accompanied by unique hurdles, our focus towards enhancing gross profit has produced promising results." The company recently announced that it has entered into a definitive share purchase agreement with 1463663 B.C. Ltd., a newly incorporated affiliate of Tierra Corp., and the company's Canadian cannabis subsidiaries, collectively referred to as the CannMart Group, to divest and sell all of the shares of the CannMart Group to the buyer for CA$5 million.

LFST

Read More

US Stocks On Track To Pause As Recent Gains, Data-Heavy Week Render Mood Cautious: Why This Analyst Thinks Market Will Chug Along Into Year-End

U.S. stocks could stall at the start of the new trading week as they come off a week when all three major averages advanced solidly. Trading in the index futures points to a modestly lower opening as investors look ahead to a data-heavy week that would offer more cues on inflation, growth, the state of the housing market, and the direction of monetary policy.

BTC